Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 69% of modeled bridge. Strengths: Occupancy Rate, Bed Count. Risks: Net-to-Gross Ratio, Revenue per Bed. Risk-adjusted uplift: $0.5M (vs $0.7M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $268K | $268K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $257K | $8K | $266K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $41K | $122K | $163K | $513K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 59.6% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $67K | $134K | $201K | $268K | $268K | $268K | $268K |
| Denial Rate Reduction | $0 | $66K | $133K | $199K | $266K | $266K | $266K | $266K |
| A/R Days Reduction | $0 | $54K | $109K | $163K | $163K | $163K | $163K | $163K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $192K | $385K | $572K | $706K | $706K | $706K | $706K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $706K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 84% / 21.2x | 89% / 24.0x | 93% / 26.7x | 95% / 28.1x | 97% / 29.4x |
| 9.0x | 79% / 18.5x | 84% / 20.9x | 88% / 23.4x | 90% / 24.6x | 92% / 25.8x |
| 10.0x | 75% / 16.4x | 79% / 18.5x | 83% / 20.7x | 85% / 21.8x | 87% / 22.9x |
| 11.0x | 71% / 14.6x | 75% / 16.6x | 79% / 18.5x | 81% / 19.5x | 83% / 20.5x |
| 12.0x | 67% / 13.1x | 72% / 14.9x | 76% / 16.7x | 78% / 17.6x | 79% / 18.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 59% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.7x, adding 5.8 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $322K | — | $322K | 2.4% |
| Year 1 | $332K | +$470K | $802K | 6.0% |
| Year 2 | $342K | +$706K | $1.0M | 7.8% |
| Year 3 | $352K | +$706K | $1.1M | 7.9% |
| Year 4 | $363K | +$706K | $1.1M | 8.0% |
| Year 5 | $373K | +$706K | $1.1M | 8.1% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $134K | $201K | $268K | $321K |
| Denial Rate Reductio | $133K | $199K | $266K | $319K |
| A/R Days Reduction | $81K | $122K | $163K | $195K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $353K | $529K | $706K | $847K |
Peer Context — Where This Hospital Sits
Key metrics vs 127 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 2.4% | -15.4% | -2.3% | 7.2% | P60 |
| Net-to-Gross | 99.2% | 32.3% | 45.9% | 59.6% | P96 |
| Occupancy | 72.3% | 20.5% | 46.1% | 69.5% | P78 |
| Rev/Bed | $669K | $290K | $537K | $964K | P62 |
| Exp/Bed | $653K | $277K | $514K | $985K | P56 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.